Angelica Bueno Barbezan received a Bachelor's degree in Biomedicine from the Centro Universitário das Faculdades Metropolitanas Unidas (2007), with majors in clinical analysis, imaging and pharmacology. Subsequently, she joined the Nuclear and Energy Research Institute of the University of São Paulo (IPEN/USP), where she obtained her Master's degree in 2012. Her master's project focused on comparing the labeling of phosphonates, specifically MDP, EDTMP and Clodronate, with potential therapeutic applications in patients with bone metastases. Furthering her dedication to research, she completed her Ph.D. at the same institution in 2017. The doctoral research focused on in vitro studies of genotoxicity and cytotoxicity in liver cells due to the formation of 2-Alkylcyclobutanones from the irradiation of fat-containing foods. Currently, she is a part of a team specializing in nano-brachytherapy, dedicating herself to the research and development of radioactive gold-198 nanoparticles for prostate cancer therapy. Her work involves carrying out biological tests, covering both in vitro and in vivo studies.